Agendia Announces Intention to List on NYSE Euronext in Amsterdam

Not for Release, Distribution or Publication in Whole or in Part, Directly or Indirectly, Into or in the United States, Australia, Canada, or Japan

AMSTERDAM, May 20, 2011 - Agendia (the "Company"), a commercial-stage molecular
diagnostic company with operations in the Netherlands and the United States,
announces today its intention to raise new funds through an initial public
offering ("IPO") on NYSE Euronext in Amsterdam.

Agendia is focused on the discovery, development and
commercialisation of molecular diagnostic products that help physicians to
make personalised treatment decisions for their cancer patients. The Company
is currently marketing its Symphony(TM) suite of four complementary breast
cancer tests, which provides a comprehensive support system for oncologists
to determine whether a patient is likely to benefit from hormonal therapy,
chemotherapy or targeted therapies. Agendia is also developing a pipeline of
genomic-based diagnostic products, including a further extension of its
breast cancer suite of tests as well as products for colon cancer and lung
cancer.

Agendia intends to use the net proceeds of the IPO primarily
to expand sales and marketing activities in its breast cancer franchise,
particularly in the United States, and to complete technical validation and
initiate commercialisation of its ColoPrint(R) colon cancer test.

Details on the offering will be announced in due course,
subject to approval of the prospectus by the Netherlands Authority for
Financial Markets and market conditions.

ABN AMRO and ING have been appointed as joint global
coordinators and joint bookrunners for the IPO. KBC Securities and Kempen &
Co are acting as co-lead managers.

About Agendia

Agendia is a commercial-stage molecular diagnostic company
focused on the discovery, development and commercialisation of genomic-based
diagnostic products to improve the quality of life for cancer patients by
providing healthcare professionals with critical information to enable safe
and effective personalised treatment. The Company's Symphony(TM) suite of
four complementary breast cancer tests, TargetPrint(R), MammaPrint(R),
BluePrint(TM) and TheraPrint(R), provides a comprehensive support system for
oncologists to determine whether a breast cancer patient is likely to benefit
from hormonal therapy, chemotherapy or targeted therapies, saving patients
from unnecessary treatments and lowering healthcare costs. Agendia's lead
test, MammaPrint(R), currently the only molecular diagnostic breast cancer
recurrence test to receive clearance from the US Food and Drug
Administration, gives physicians a tool to clearly and decidedly separate
"high" risk from "low" risk recurrence in early stage breast cancer patients,
thereby better gauging the "high" risk patients' need for chemotherapy.
Agendia is advancing a pipeline of new products, which includes a further
extension of its breast cancer suite of tests as well as products for colon
cancer and lung cancer. The Company's research and development activities are
driven by its deep scientific roots and supported by collaborations with
leading academic consortia, cancer centres and pharmaceutical companies.

Agendia was founded in 2003 as a spin-off of the Netherlands
Cancer Institute and is based in Amsterdam, the Netherlands, and Irvine,
California, United States. For more information, please visit
www.agendia.com .

Disclaimer

This announcement and the information contained herein are not
for distribution in or into the United States of America (including its
territories and possessions, any state of the United States of America and
the District of Columbia) (the "United States"), Australia, Canada or Japan.
This announcement does not constitute, or form part of, an offer to sell or a
solicitation of any offer to purchase the shares of Agendia (the "Company",
and such shares, the "Securities") in the United States, Australia, Canada,
Japan or in any other jurisdiction where such offer or sale could be
unlawful.

The Securities have not been and will not be registered under
the US Securities Act of 1933, as amended (the "Securities Act"), or with any
securities regulatory authority of any state or other jurisdiction of the
United States. Consequently, the Securities may not be offered, sold, resold,
transferred, delivered or distributed, directly or indirectly, into or within
the United States except pursuant to an exemption from the registration
requirements of the Securities Act and in compliance with any applicable
securities laws of any state or other jurisdiction of the United States. No
public offering of the Securities is being made in the United States.

This communication is only addressed to, and directed at,
persons in member states of the European Economic Area who are "qualified
investors" within the meaning of Article 2(1)(e) of the Prospectus Directive
("Qualified Investors"). For the purposes of this provision, the expression
"Prospectus Directive" means Directive 2003/71/EC (and amendments thereto,
including Directive 2010/73/EC, to the extent implemented in the Relevant
Member State) and includes any relevant implementing measure in each member
state of the European Economic Area which has implemented the Prospectus
Directive. This document is an advertisement and not a prospectus for the
purpose of the Prospectus Directive. A prospectus prepared pursuant to the
Prospectus Directive is intended to be published, which, when published, can
be obtained from Agendia. Investors should not subscribe for any securities
referred to in this document except on the basis of information contained in
the prospectus.

In addition, in the United Kingdom, this communication is
being distributed only to, and is directed only at, Qualified Investors (i)
who have professional experience in matters relating to investments who fall
within the definition of "investment professional" in Article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as
amended (the "Order"), or (ii) who are high net worth companies,
unincorporated associations and partnerships and trustees of high value
trusts as described in Article 49(2) of the Order, and (iii) other persons to
whom it may otherwise lawfully be communicated (all such persons together
being referred to as "relevant persons"). Any investment or investment
activity to which this communication relates is available only to and will
only be engaged in with such persons. This communication must not be acted on
or relied on (i) in the United Kingdom, by persons who are not relevant
persons and (ii) in any member state of the European Economic Area other than
the United Kingdom, by persons who are not Qualified Investors.

In connection with the Offering, one of the Underwriters (the
"Stabilising Manager") (or persons acting on behalf of the Stabilising
Manager) may over-allot shares or effect transactions with a view to
supporting the market price of the shares at a level higher than that which
might otherwise prevail. However, there is no assurance that the Stabilising
Manager (or persons acting on behalf of the Stabilising Manager) will
undertake stabilisation action. Any stabilisation action may begin on or
after the date on which adequate public disclosure of the final price of the
shares is made and, if begun, may be ended at any time, but it must end no
later than 30 days after the date of commencement of trading of the shares.

The information, opinions and forward-looking statements
contained in this release speak only as at its date, and are subject to
change without notice.

All investment is subject to risk. The price of the securities
offered may fluctuate. Past performance is no guarantee of future returns.
Potential investors are advised to seek expert financial advice before making
any investment decision.

Aan de belegging zijn risico's verbonden. De waarde van de
aangeboden effecten kan fluctueren. Rendementen uit het verleden zijn geen
garantie voor de toekomst. Potentiële beleggers wordt geadviseerd om eerst
hun eigen beleggingsadviseur te raadplegen alvorens een beleggingsbesluit te
nemen.

    For further information, please contact:

    Agendia
    Dr. Bernhard Sixt, President & CEO
    Investorrelations@agendia.com

    International media and investor enquiries
    M:Communications
    Mary-Jane Elliott / Emma Thompson
    Tel: +44(0)20-7920-2345, E-mail: Agendia@mcomgroup.com

    Dutch media enquiries
    Huijskens Communications
    Ian Bickerton
    Tel +31(0)20-685-5955
    Email: i.bickerton@huijskens.nl

.